Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. However, there is significant inter-individual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate, or aggressive disease course is very limited. There is therefore a need for integrated predictive tools to inform individualised treatment decision-making. FutureMS is a nationally representative, prospective observation cohort study comprising of 440 participants with a new diagnosis of relapsing remitting MS living in Scotland between May 2016 and March 2019. Established with the aim of addressing this need for individualised predictive tools, the cohort is designed to combine detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow up at year one is complete and longer term follow up is planned, beginning at five years after first visit. The study aims to explore the pathobiology and determinants of disease heterogeneity in MS. Here we describe the cohort design and present a profile of the participants at baseline and one year of follow up.

中文翻译：

---

FutureMS 队列概况：一项关于复发缓解型多发性硬化症的苏格兰多中心初始队列研究

多发性硬化症 (MS) 是一种免疫介导的中枢神经系统神经炎性疾病，在工业化国家是工作年龄人群进行性神经功能障碍的最常见原因。然而，在疾病活动和对治疗的反应方面存在显着的个体间异质性。目前，在诊断时预测谁将患有良性、中期或侵袭性病程的能力非常有限。因此，需要集成的预测工具来为个性化治疗决策提供信息。FutureMS 是一项具有全国代表性的前瞻性观察队列研究，包括 2016 年 5 月至 2019 年 3 月期间居住在苏格兰的 440 名新诊断为复发缓解型 MS 的参与者。该队列旨在满足对个性化预测工具的这种需求，旨在将详细的临床表型与疾病活动和进展的成像、遗传和生物标志物指标相结合。第一年的招募、基线评估和随访已完成，并计划在首次访问后五年开始进行更长期的随访。该研究旨在探索 MS 疾病异质性的病理生物学和决定因素。在这里，我们描述了队列设计，并在基线和一年的随访中介绍了参与者的概况。从第一次访问五年后开始。该研究旨在探索 MS 疾病异质性的病理生物学和决定因素。在这里，我们描述了队列设计，并在基线和一年的随访中介绍了参与者的概况。从第一次访问五年后开始。该研究旨在探索 MS 疾病异质性的病理生物学和决定因素。在这里，我们描述了队列设计，并在基线和一年的随访中介绍了参与者的概况。